Terms: = Skin cancer AND COX6C, P09669, 1345, ENSG00000164919 AND Treatment
7 results:
1. Tyrosine kinase inhibitors versus radiation therapy in unresectable dermatofibrosarcoma protuberans (DFSP): A narrative systematic review.
Henry OS; Platoff R; Cerniglia KS; Batchu S; Goodwin BJ; Sandilos G; Adams A; Hong YK
Am J Surg; 2023 Feb; 225(2):268-274. PubMed ID: 36184329
[TBL] [Abstract] [Full Text] [Related]
2. Delayed Metastatic Polypoid Nodular Melanoma Diagnosis During COVID-19 Pandemic, Successful treatment With Surgery and Nivolumab.
Bradu S; Siegel D; Loyal J; Leaf A; Kurtti A; Alapati U; Jagdeo J
J Drugs Dermatol; 2021 Dec; 20(12):1343-1345. PubMed ID: 34898148
[TBL] [Abstract] [Full Text] [Related]
3. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.
Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
Lancet Oncol; 2018 Oct; 19(10):1315-1327. PubMed ID: 30219628
[TBL] [Abstract] [Full Text] [Related]
4. MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial.
Dreno B; Thompson JF; Smithers BM; Santinami M; Jouary T; Gutzmer R; Levchenko E; Rutkowski P; Grob JJ; Korovin S; Drucis K; Grange F; Machet L; Hersey P; Krajsova I; Testori A; Conry R; Guillot B; Kruit WHJ; Demidov L; Thompson JA; Bondarenko I; Jaroszek J; Puig S; Cinat G; Hauschild A; Goeman JJ; van Houwelingen HC; Ulloa-Montoya F; Callegaro A; Dizier B; Spiessens B; Debois M; Brichard VG; Louahed J; Therasse P; Debruyne C; Kirkwood JM
Lancet Oncol; 2018 Jul; 19(7):916-929. PubMed ID: 29908991
[TBL] [Abstract] [Full Text] [Related]
5. Nivolumab versus ipilimumab in the treatment of advanced melanoma: a critical appraisal: ORIGINAL ARTICLE: Wolchok JD, Chiarion-Sileni V, Gonzalez R et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 2017; 377:1345-56.
Wan MT; Ming ME
Br J Dermatol; 2018 Aug; 179(2):296-300. PubMed ID: 29766492
[TBL] [Abstract] [Full Text] [Related]
6. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion-Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
Lancet Oncol; 2018 May; 19(5):603-615. PubMed ID: 29573941
[TBL] [Abstract] [Full Text] [Related]
7. Accelerated radiotherapy with concomitant boost technique (69.5 Gy/5 weeks) : an alternative in the treatment of locally advanced head and neck cancer.
Kubes J; Cvek J; Vondracek V; Pala M; Feltl D
Strahlenther Onkol; 2011 Oct; 187(10):651-5. PubMed ID: 21947124
[TBL] [Abstract] [Full Text] [Related]
